Sanofi (SNYNF) Shares Outstanding (Diluted Average) (2009 - 2025)
Sanofi's (SNYNF) quarterly Shares Outstanding (Diluted Average) came in at $1.4 billion in Q4 2025, up 6.29% year-on-year from $1.3 billion in Q4 2024, and up 52633.8% quarter-over-quarter from $2.7 million in Q2 2025.
Sanofi (SNYNF) Shares Outstanding (Diluted Average) (2009 - 2025) Analysis & Trends
Sanofi has disclosed Shares Outstanding (Diluted Average) across 17 years of filings, most recently posting $1.4 billion for Q4 2025.
- Shares Outstanding (Diluted Average) for Q4 2025 came in at $1.4 billion, up 6.29% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.4 billion (up 6.29% YoY), and the FY2025 annual result was $1.4 billion, up 6.29% from the prior year.
- Shares Outstanding (Diluted Average) came in at $1.4 billion for Q4 2025 at Sanofi, up from $2.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $1.4 billion in Q4 2021 to a low of $1.8 million in Q2 2024.
- The 5-year median for Shares Outstanding (Diluted Average) is $642.7 million (2023), against an average of $685.4 million.
- Across the five-year window, Shares Outstanding (Diluted Average) slumped 67.41% in 2021 and jumped 54.12% in 2025, its largest moves.
- Sanofi's Shares Outstanding (Diluted Average) stood at $1.4 billion in 2021, then fell by 10.82% to $1.3 billion in 2022, then increased by 5.42% to $1.4 billion in 2023, then slipped by 0.71% to $1.3 billion in 2024, then climbed by 6.29% to $1.4 billion in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $1.4 billion (Q4 2025), $2.7 million (Q2 2025), and $1.3 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 895.90 Mn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 2.45 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 1.77 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | - |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 544.00 Mn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 1.25 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 5.73 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | - |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.43 Bn |
| Jun 30, 2025 | 2.71 Mn |
| Dec 31, 2024 | 1.34 Bn |
| Jun 30, 2024 | 1.76 Mn |
| Dec 31, 2023 | 1.35 Bn |
| Jun 30, 2023 | 2.97 Mn |
| Dec 31, 2022 | 1.28 Bn |
| Jun 30, 2022 | 2.71 Mn |
| Dec 31, 2021 | 1.44 Bn |
| Jun 30, 2021 | 2.65 Mn |
| Dec 31, 2020 | 1.50 Bn |
| Jun 30, 2020 | 8.13 Mn |
| Dec 31, 2019 | 33,206.63 |
| Jun 30, 2019 | 943,856.84 |
| Dec 31, 2018 | 1.43 Bn |
| Jun 30, 2018 | 1.69 Mn |
| Dec 31, 2017 | 1.49 Bn |
| Jun 30, 2017 | 5.83 Mn |
| Dec 31, 2016 | 3.92 Mn |
| Jun 30, 2016 | 1.95 Mn |